Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

505
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
505
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

616
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
616
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

490
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
490
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

443
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
443
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Antiplatelet Therapy: The Promise and Complexity of Pharmacogenomic Antiplatelet Therapy.

Circulation. Cardiovascular interventions·2026
Same author

Diabetes and cancer: therapeutic implications.

Cardio-oncology (London, England)·2026
Same author

Measuring Adherence to Multiple Medications Using Guideline-Directed Medical Therapy as a Model.

medRxiv : the preprint server for health sciences·2025
Same author

Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory.

JACC. Heart failure·2025
Same author

Platelet reactivity expression score in diabetes mellitus.

Blood vessels, thrombosis & hemostasis·2025
Same author

Accuracy of Electronic Health Record-Based Definitions for Patients with Heart Failure.

The American journal of medicine·2025
Same journal

Artificial Intelligence in Echocardiography for Valvular Heart Disease.

Trends in cardiovascular medicine·2026
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Heart failure guidelines: What's new?

Lampros Papadimitriou1, Carine E Hamo1, Javed Butler1

  • 1From the Division of Cardiology, Department of Medicine, Stony Brook University, Stony Brook, NY, USA.

Trends in Cardiovascular Medicine
|February 11, 2017
PubMed
Summary
This summary is machine-generated.

New heart failure medications, valsartan/sacubitril and ivabradine, offer additional survival benefits for patients with reduced ejection fraction. These drugs target key systems involved in heart failure progression.

Keywords:
GuidelinesHeart failureIvabradineValsartan/sacubitril

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure (HF) is a widespread condition impacting millions globally.
  • Current HF treatments focus on inhibiting the renin-angiotensin-aldosterone and sympathetic autonomic systems.
  • Despite advances, improved therapies are needed for specific HF patient groups.

Purpose of the Study:

  • To review the impact of newly approved heart failure medications.
  • To assess the benefits of valsartan/sacubitril and ivabradine in HF management.
  • To evaluate their role in heart failure with reduced ejection fraction (HFrEF).

Main Methods:

  • Analysis of the 2016 focused pharmacologic update for Heart Failure Guidelines.
  • Review of clinical trial data for valsartan/sacubitril and ivabradine.
  • Examination of mortality and morbidity outcomes in HFrEF subpopulations.

Main Results:

  • Valsartan/sacubitril and ivabradine are newly approved regimens for HF.
  • These medications demonstrate additional benefits in reducing mortality and morbidity.
  • The advantages are particularly noted in heart failure patients with reduced ejection fraction.

Conclusions:

  • Valsartan/sacubitril and ivabradine represent significant advancements in HF pharmacotherapy.
  • These agents offer enhanced benefits for HFrEF patients.
  • Guideline-directed medical therapy continues to evolve with novel drug introductions.